Cargando…

Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories

BACKGROUND: The Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTC-VIMC) was created to provide standardized immunogenicity monitoring services for HIV vaccine trials. The ex vivo interferon-gamma (IFN-γ) ELISpot is used extensively as a primary immunogenicity assay to assess T cell-base...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gill, Dilbinder K., Huang, Yunda, Levine, Gail L., Sambor, Anna, Carter, Donald K., Sato, Alicia, Kopycinski, Jakub, Hayes, Peter, Hahn, Bridget, Birungi, Josephine, Tarragona-Fiol, Tony, Wan, Hong, Randles, Mark, Cooper, Andrew Raxworthy, Ssemaganda, Aloysius, Clark, Lorna, Kaleebu, Pontiano, Self, Steven G., Koup, Richard, Wood, Blake, McElrath, M. Juliana, Cox, Josephine H., Hural, John, Gilmour, Jill
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001861/ https://www.ncbi.nlm.nih.gov/pubmed/21179404 http://dx.doi.org/10.1371/journal.pone.0014330

Ejemplares similares

P16-19. Statistical design and analysis of the CAVD-VIMC Elispot transfer study 001
por: Huang, Y, et al.
Publicado: (2009)

Effect of Couples Counselling on Reported HIV Risk Behaviour among HIV Serodiscordant Couples by ART Use, HIV Status and Gender in Rural Uganda
por: King, Rachel, et al.
Publicado: (2015)

In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers
por: Vasan, Sandhya, et al.
Publicado: (2011)

A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults
por: Keefer, Michael C., et al.
Publicado: (2012)

Durability of non-nucleotide reverse transcriptase inhibitor-based first-line ART regimens after 7 years of treatment in rural Uganda: A prospective cohort study
por: Nanfuka, Mastula, et al.
Publicado: (2021)

Broad HIV Epitope Specificity and Viral Inhibition Induced by Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults
por: Kopycinski, Jakub, et al.
Publicado: (2014)

Modified ELISPOT: Modifications of the Elispot Assay for T Cell Monitoring in Cancer Vaccine Trials
por: Malyguine, Anatoli
Publicado: (2005)

P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
por: Self, S, et al.
Publicado: (2009)

Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical Trials
por: Sarzotti-Kelsoe, Marcella, et al.
Publicado: (2009)

Feasibility and acceptability of mobile phone short message service as a support for patients receiving antiretroviral therapy in rural Uganda: a cross-sectional study
por: Kim, Jiho, et al.
Publicado: (2015)

Risky sexual behavior among patients on long-term antiretroviral therapy: a prospective cohort study in urban and rural Uganda
por: Okoboi, Stephen, et al.
Publicado: (2018)

Community-based ART distribution system can effectively facilitate long-term program retention and low-rates of death and virologic failure in rural Uganda
por: Okoboi, Stephen, et al.
Publicado: (2015)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants
por: Espy, Nicole, et al.
Publicado: (2023)

Response definition criteria for ELISPOT assays revisited
por: Moodie, Z., et al.
Publicado: (2010)

Performance of International AIDS Vaccine Initiative African clinical research laboratories in standardised ELISpot and peripheral blood mononuclear cell processing in support of HIV vaccine clinical trials
por: Langat, Robert K., et al.
Publicado: (2021)

P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study
por: Maxfield, LF, et al.
Publicado: (2009)

Longitudinal Assessment of an ELISPOT Test for Mycobacterium tuberculosis Infection
por: Hill, Philip C, et al.
Publicado: (2007)

Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT
por: Maecker, Holden T, et al.
Publicado: (2005)

ELISPOT Cell Analysis Assay: Searching for Extracellular Footprints
por: Kalyuzhny, Alexander E.
Publicado: (2011)

P15-05. Evaluation and recommendations on good clinical laboratory practice (GCLP) guidelines for phase I-III HIV vaccine clinical trials
por: Sarzotti-Kelsoe, M, et al.
Publicado: (2009)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
por: Huang, Yunda, et al.
Publicado: (2023)

Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases
por: Aiken, Alexander M, et al.
Publicado: (2006)

High Reproducibility of ELISPOT Counts from Nine Different Laboratories
por: Sundararaman, Srividya, et al.
Publicado: (2015)

ELISPOT assays and their diagnostic potential in Lyme disease and Lyme neuroborreliosis
por: Ettischer‐Schmid, N., et al.
Publicado: (2020)

Lack of Effectiveness of Antiretroviral Therapy in Preventing HIV Infection in Serodiscordant Couples in Uganda: An Observational Study
por: Birungi, Josephine, et al.
Publicado: (2015)

Emergent Electroweak Gravity
por: McElrath, Bob
Publicado: (2008)

Laboratory tests for the cosmic neutrino background using beta-decaying nuclei
por: McElrath, Bob
Publicado: (2009)

On The Origin of Neutrino Mass and Mixing in the Standard Model
por: McElrath, Bob
Publicado: (2009)

Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans
por: Pine, Samuel O., et al.
Publicado: (2011)

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study
por: Huang, Yunda, et al.
Publicado: (2014)

P06-06. Capacity building for HIV vaccine trials in Africa through South-South collaboration
por: Mpendo, J, et al.
Publicado: (2009)

$h \to \mu^{+}\mu^{-}$ via Gluon Fusion at the LHC
por: Han, T, et al.
Publicado: (2002)

ELISPOT Refinement Using Spot Morphology for Assessing Host Responses to Tuberculosis
por: Sibley, Laura S., et al.
Publicado: (2012)

Defining ELISpot cut-offs from unreplicated test and control wells
por: Alexander, Neal, et al.
Publicado: (2013)

Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation
por: Zitzner, Jennifer R., et al.
Publicado: (2012)

Dissecting the T Cell Response: Proliferation Assays vs. Cytokine Signatures by ELISPOT
por: Anthony, Donald D., et al.
Publicado: (2012)

Stepping up ELISpot: Multi-Level Analysis in FluoroSpot Assays
por: Janetzki, Sylvia, et al.
Publicado: (2014)

How Can Elispot Add Information to Improve Knowledge on Tropical Diseases?
por: Lima-Junior, Josué da Costa, et al.
Publicado: (2017)

Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials
por: Stevens, Wendy, et al.
Publicado: (2008)

Prevention of the sexual transmission of HIV-1: preparing for success
por: Cohen, Myron S, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_466nb2h254rcu8tiolms0l2h57